Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatīts, atopisks - citi dermatoloģiski preparāti - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hipofīzes un hipotalāma hormoni un to analogi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneimokoku infekcijas - vakcīnas - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. skatīt nodaļas 4. 4 un 5. 1, lai iegūtu informāciju par aizsardzību pret specifiskiem pneimokoku serotipiem. apexxnar should be used in accordance with official recommendations. .

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - elpceļu sindciālu vīrusu infekcijas - vakcīnas - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. skatīt nodaļas 4. 2 un 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Latvija - latviešu - Zāļu valsts aģentūra

pfizer europe ma eeig, united kingdom - nicergolīns - apvalkotās tabletes - 30 mg

Latvija - latviešu - Zāļu valsts aģentūra

pfizer enterprises sarl, luxembourg - kabergolīns - tablete - 0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - medroksiprogesterona acetāts - suspensija injekcijām pilnšļircē - 150 mg/1 ml

Latvija - latviešu - Zāļu valsts aģentūra

pfizer europe ma eeig, belgium - medroksiprogesterona acetāts - suspensija injekcijām - 150 mg/1 ml

Latvija - latviešu - Zāļu valsts aģentūra

pfizer enterprises sarl, luxembourg - metilprednizolona acetāts - suspensija injekcijām - 40 mg/1 ml